Retinaldehyde dehydrogenase 2 as a molecular adjuvant for enhancement of mucosal immunity during DNA vaccination

Susan A. Holechek, Megan S. McAfee, Lizbeth M. Nieves, Vanessa P. Guzman, Kavita Manhas, Timothy Fouts, Kenneth Bagley, Joseph Blattman

Research output: Contribution to journalArticle

Abstract

In order for vaccines to induce efficacious immune responses against mucosally transmitted pathogens, such as HIV-1, activated lymphocytes must efficiently migrate to and enter targeted mucosal sites. We have previously shown that all-trans retinoic acid (ATRA) can be used as a vaccine adjuvant to enhance mucosal CD8+ T cell responses during vaccination and improve protection against mucosal viral challenge. However, the ATRA formulation is incompatible with most recombinant vaccines, and the teratogenic potential of ATRA at high doses limits its usage in many clinical settings. We hypothesized that increasing in vivo production of retinoic acid (RA) during vaccination with a DNA vector expressing retinaldehyde dehydrogenase 2 (RALDH2), the rate-limiting enzyme in RA biosynthesis, could similarly provide enhanced programming of mucosal homing to T cell responses while avoiding teratogenic effects. Administration of a RALDH2- expressing plasmid during immunization with a HIVgag DNA vaccine resulted in increased systemic and mucosal CD8+ T cell numbers with an increase in both effector and central memory T cells. Moreover, mice that received RALDH2 plasmid during DNA vaccination were more resistant to intravaginal challenge with a recombinant vaccinia virus expressing the same HIVgag antigen (VACVgag). Thus, RALDH2 can be used as an alternative adjuvant to ATRA during DNA vaccination leading to an increase in both systemic and mucosal T cell immunity and better protection from viral infection at mucosal sites.

Original languageEnglish (US)
Pages (from-to)5629-5635
Number of pages7
JournalVaccine
Volume34
Issue number46
DOIs
StatePublished - Nov 4 2016

Fingerprint

retinaldehyde
Retinaldehyde
mucosal immunity
Mucosal Immunity
retinoic acid
Tretinoin
adjuvants
Oxidoreductases
Vaccination
vaccination
T-lymphocytes
DNA
T-Lymphocytes
recombinant vaccines
plasmids
Plasmids
Vaccines
vaccine adjuvants
Vaccinia virus
Synthetic Vaccines

Keywords

  • HIV DNA vaccine
  • Mucosal protection
  • RALDH2 adjuvant
  • Retinoic acid

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Cite this

Retinaldehyde dehydrogenase 2 as a molecular adjuvant for enhancement of mucosal immunity during DNA vaccination. / Holechek, Susan A.; McAfee, Megan S.; Nieves, Lizbeth M.; Guzman, Vanessa P.; Manhas, Kavita; Fouts, Timothy; Bagley, Kenneth; Blattman, Joseph.

In: Vaccine, Vol. 34, No. 46, 04.11.2016, p. 5629-5635.

Research output: Contribution to journalArticle

Holechek, SA, McAfee, MS, Nieves, LM, Guzman, VP, Manhas, K, Fouts, T, Bagley, K & Blattman, J 2016, 'Retinaldehyde dehydrogenase 2 as a molecular adjuvant for enhancement of mucosal immunity during DNA vaccination', Vaccine, vol. 34, no. 46, pp. 5629-5635. https://doi.org/10.1016/j.vaccine.2016.09.013
Holechek, Susan A. ; McAfee, Megan S. ; Nieves, Lizbeth M. ; Guzman, Vanessa P. ; Manhas, Kavita ; Fouts, Timothy ; Bagley, Kenneth ; Blattman, Joseph. / Retinaldehyde dehydrogenase 2 as a molecular adjuvant for enhancement of mucosal immunity during DNA vaccination. In: Vaccine. 2016 ; Vol. 34, No. 46. pp. 5629-5635.
@article{0743112c750e46b2931fdac1b68e1851,
title = "Retinaldehyde dehydrogenase 2 as a molecular adjuvant for enhancement of mucosal immunity during DNA vaccination",
abstract = "In order for vaccines to induce efficacious immune responses against mucosally transmitted pathogens, such as HIV-1, activated lymphocytes must efficiently migrate to and enter targeted mucosal sites. We have previously shown that all-trans retinoic acid (ATRA) can be used as a vaccine adjuvant to enhance mucosal CD8+ T cell responses during vaccination and improve protection against mucosal viral challenge. However, the ATRA formulation is incompatible with most recombinant vaccines, and the teratogenic potential of ATRA at high doses limits its usage in many clinical settings. We hypothesized that increasing in vivo production of retinoic acid (RA) during vaccination with a DNA vector expressing retinaldehyde dehydrogenase 2 (RALDH2), the rate-limiting enzyme in RA biosynthesis, could similarly provide enhanced programming of mucosal homing to T cell responses while avoiding teratogenic effects. Administration of a RALDH2- expressing plasmid during immunization with a HIVgag DNA vaccine resulted in increased systemic and mucosal CD8+ T cell numbers with an increase in both effector and central memory T cells. Moreover, mice that received RALDH2 plasmid during DNA vaccination were more resistant to intravaginal challenge with a recombinant vaccinia virus expressing the same HIVgag antigen (VACVgag). Thus, RALDH2 can be used as an alternative adjuvant to ATRA during DNA vaccination leading to an increase in both systemic and mucosal T cell immunity and better protection from viral infection at mucosal sites.",
keywords = "HIV DNA vaccine, Mucosal protection, RALDH2 adjuvant, Retinoic acid",
author = "Holechek, {Susan A.} and McAfee, {Megan S.} and Nieves, {Lizbeth M.} and Guzman, {Vanessa P.} and Kavita Manhas and Timothy Fouts and Kenneth Bagley and Joseph Blattman",
year = "2016",
month = "11",
day = "4",
doi = "10.1016/j.vaccine.2016.09.013",
language = "English (US)",
volume = "34",
pages = "5629--5635",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "46",

}

TY - JOUR

T1 - Retinaldehyde dehydrogenase 2 as a molecular adjuvant for enhancement of mucosal immunity during DNA vaccination

AU - Holechek, Susan A.

AU - McAfee, Megan S.

AU - Nieves, Lizbeth M.

AU - Guzman, Vanessa P.

AU - Manhas, Kavita

AU - Fouts, Timothy

AU - Bagley, Kenneth

AU - Blattman, Joseph

PY - 2016/11/4

Y1 - 2016/11/4

N2 - In order for vaccines to induce efficacious immune responses against mucosally transmitted pathogens, such as HIV-1, activated lymphocytes must efficiently migrate to and enter targeted mucosal sites. We have previously shown that all-trans retinoic acid (ATRA) can be used as a vaccine adjuvant to enhance mucosal CD8+ T cell responses during vaccination and improve protection against mucosal viral challenge. However, the ATRA formulation is incompatible with most recombinant vaccines, and the teratogenic potential of ATRA at high doses limits its usage in many clinical settings. We hypothesized that increasing in vivo production of retinoic acid (RA) during vaccination with a DNA vector expressing retinaldehyde dehydrogenase 2 (RALDH2), the rate-limiting enzyme in RA biosynthesis, could similarly provide enhanced programming of mucosal homing to T cell responses while avoiding teratogenic effects. Administration of a RALDH2- expressing plasmid during immunization with a HIVgag DNA vaccine resulted in increased systemic and mucosal CD8+ T cell numbers with an increase in both effector and central memory T cells. Moreover, mice that received RALDH2 plasmid during DNA vaccination were more resistant to intravaginal challenge with a recombinant vaccinia virus expressing the same HIVgag antigen (VACVgag). Thus, RALDH2 can be used as an alternative adjuvant to ATRA during DNA vaccination leading to an increase in both systemic and mucosal T cell immunity and better protection from viral infection at mucosal sites.

AB - In order for vaccines to induce efficacious immune responses against mucosally transmitted pathogens, such as HIV-1, activated lymphocytes must efficiently migrate to and enter targeted mucosal sites. We have previously shown that all-trans retinoic acid (ATRA) can be used as a vaccine adjuvant to enhance mucosal CD8+ T cell responses during vaccination and improve protection against mucosal viral challenge. However, the ATRA formulation is incompatible with most recombinant vaccines, and the teratogenic potential of ATRA at high doses limits its usage in many clinical settings. We hypothesized that increasing in vivo production of retinoic acid (RA) during vaccination with a DNA vector expressing retinaldehyde dehydrogenase 2 (RALDH2), the rate-limiting enzyme in RA biosynthesis, could similarly provide enhanced programming of mucosal homing to T cell responses while avoiding teratogenic effects. Administration of a RALDH2- expressing plasmid during immunization with a HIVgag DNA vaccine resulted in increased systemic and mucosal CD8+ T cell numbers with an increase in both effector and central memory T cells. Moreover, mice that received RALDH2 plasmid during DNA vaccination were more resistant to intravaginal challenge with a recombinant vaccinia virus expressing the same HIVgag antigen (VACVgag). Thus, RALDH2 can be used as an alternative adjuvant to ATRA during DNA vaccination leading to an increase in both systemic and mucosal T cell immunity and better protection from viral infection at mucosal sites.

KW - HIV DNA vaccine

KW - Mucosal protection

KW - RALDH2 adjuvant

KW - Retinoic acid

UR - http://www.scopus.com/inward/record.url?scp=84992363283&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84992363283&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2016.09.013

DO - 10.1016/j.vaccine.2016.09.013

M3 - Article

C2 - 27670072

AN - SCOPUS:84992363283

VL - 34

SP - 5629

EP - 5635

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 46

ER -